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Abstract
Background: The inflammatory chemokines CCL2 (MCP-1) & CCL5 (RANTES) and the inflammatory cytokines TNFa
& IL-1b were shown to contribute to breast cancer development and metastasis. In this study, we wished to
determine whether there are associations between these factors along stages of breast cancer progression, and to
identify the possible implications of these factors to disease course.
Methods: The expression of CCL2, CCL5, TNFa and IL-1b was determined by immunohistochemistry in patients
diagnosed with: (1) Benign breast disorders (=healthy individuals); (2) Ductal Carcinoma In Situ (DCIS); (3)
Invasive Ducal Carcinoma without relapse (IDC-no-relapse); (4) IDC-with-relapse. Based on the results
obtained, breast tumor cells were stimulated by the inflammatory cytokines, and epithelial-to-mesenchymal
transition (EMT) was determined by flow cytometry, confocal analyses and adhesion, migration and invasion
experiments.
Results: CCL2, CCL5, TNFa and IL-1b were expressed at very low incidence in normal breast epithelial cells, but
their incidence was significantly elevated in tumor cells of the three groups of cancer patients. Significant
associations were found between CCL2 & CCL5 and TNFa & IL-1b in the tumor cells in DCIS and IDC-no-relapse
patients. In the IDC-with-relapse group, the expression of CCL2 & CCL5 was accompanied by further elevated
incidence of TNFa & IL-1b expression. These results suggest progression-related roles for TNFa and IL-1b in breast
cancer, as indeed indicated by the following: (1) Tumors of the IDC-with-relapse group had significantly higher
persistence of TNFa and IL-1b compared to tumors of DCIS or IDC-no-relapse; (2) Continuous stimulation of the
tumor cells by TNFa (and to some extent IL-1b) has led to EMT in the tumor cells; (3) Combined analyses with
relevant clinical parameters suggested that IL-1b acts jointly with other pro-malignancy factors to promote disease
relapse.
Conclusions: Our findings suggest that the coordinated expression of CCL2 & CCL5 and TNFa & IL-1b may be
important for disease course, and that TNFa & IL-1b may promote disease relapse. Further in vitro and in vivo
studies are needed for determination of the joint powers of the four factors in breast cancer, as well as analyses of
their combined targeting in breast cancer.
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Breast cancer provides a typical example of an inflamma-
tion-linked malignant disease. Breast tumors are enriched
with inflammatory constituents, including cells that are
polarized to the tumor-promoting phenotype, and solu-
ble factors. Cumulative findings of a large number of stu-
dies indicate that many of the inflammatory components
present in the tumor microenvironment actively support
breast cancer development and progression [1-4].
Recently, much attention has been given to the roles
of inflammatory chemokines and cytokines in breast
cancer, with emphasis on the chemokines CCL2 and
CCL5, and the cytokines tumor necrosis factor a
(TNFa)a n di n t e r l e u k i n1 b (IL-1b). While each compo-
nent has been studied meticulously, too little considera-
tion has been given to possible associations and
interactions between the inflammatory mediators, and
to their joint presence, as part of the inflammatory
microenvironment, in breast cancer. The identification
of the inflammatory setup prevailing in breast cancer
may be instrumental in providing us with a better basis
for the future design of improved therapeutic modalities,
and of advanced diagnostic and prognostic tools.
In this study, we asked if associations exist between
t h ei n f l a m m a t o r yc h e m o k i n e sC C L 2&C C L 5a n dt h e
inflammatory cytokines TNFa &I L - 1 b in breast cancer.
All four factors are expressed in breast tumors, they
exert a diverse array of activities that support malig-
nancy and they were shown to be directly involved in
promoting tumor growth and metastasis in animal
model systems of breast cancer (Refs [3,5-24] for CCL2
& CCL5, [25-59] for TNFa and IL-1b). Out of the four
factors, TNFa is of special interest because of reports
showing that under specific circumstances it may have
cytotoxic and anti-tumor effects in several malignant
diseases [25,60,61].
The chemokines CCL2 and CCL5 are categorized as
“inflammatory chemokines”, and as such they are usually
not constitutively expressed by normal tissue cells.
Rather, their expression is induced by inflammatory
insults that prevail in the course of immune functions,
including by stimulation with TNFa and IL-1b.T h e
inter-connection between CCL2 & CCL5 and TNFa &
IL-1b in the immune setting suggests that similar inter-
actions exist between these chemokines and cytokines
also within the inflammatory context of breast tumors.
It is possible that TNFa &I L - 1 b and the two chemo-
kines are interrelated in breast tumor cells, and that
these four factors establish associations that may even-
tually contribute to tumor growth and metastasis.
To determine if this indeed the case, we have initiated
this study by determining the expression patterns of
CCL2, CCL5, TNFa and IL-1b in biopsy sections of
healthy individuals and in breast cancer patients at dif-
ferent progression stages of disease. While only negligi-
ble staining of the factors was detected in infiltrating
leukocytes in all groups, there was substantial expression
of all four factors in breast tumor cells. Therefore, we
focused in this study on the identification of expression
patterns of CCL2, CCL5, TNFa and IL-1b in normal
and malignant breast epithelial cells, and their potential
contribution to disease course.
The results of our study indicate that significant asso-
ciations exist between CCL2 & CCL5 and TNFa &I L -
1b in breast cancer, along different stages of disease
course. Furthermore, the results of this study support
the possibility that TNFa &I L - 1 b play an important
role in disease progression. These two cytokines were
found to be highly persistent in tumors of patients suf-
fering from relapsed disease. In addition, we found that
they promoted processes that are required for disease
progression and local recurrence, such as EMT which
was induced mainly by TNFa.
The tumor-promoting activities of the inflammatory
mediators CCL2 & CCL5 and TNFa &I L - 1 b in breast
cancer are not fully overlapping (references above),
therefore their coordinated expression may eventually
provide advantage to the developing and metastasizing
tumor. This possibility emphasizes the need to deter-
mine the joint powers of the four factors together in
breast cancer, by using in vitro and in vivo model sys-
tems. Moreover, our results suggest an important role
for TNFa in breast malignancy, because the cytokine
has substantial ability to promote progression-related
processes by inducing EMT processes in the tumor cells.
Methods
Patients
This study included 38 healthy individuals who were
diagnosed with benign breast disorders that included
fibrocystic changes, hyperplastic changes and benign
tumors (this group is termed herein “Benign”). The
study also included 88 breast cancer patients, who were
divided to three groups: (1) 30 patients with DCIS.
Since DCIS is a less malignant form of disease that
rarely develops to IDC [62-64], the DCIS group included
patients in whom disease has not progressed to IDC in
the course of 5-10 years of follow up; (2) 23 patients
with IDC, who remained disease free in the course of 5-
10 years of follow up (IDC-no-relapse); (3) 35 patients
with IDC who relapsed with metastases or local tumor/
s, or who died of breast cancer, in 5-10 years of follow
up (IDC-with-relapse).
The characteristics of the study patients who were
diagnosed with DCIS, IDC-no-relapse and IDC-with-
relapse are presented in Table 1. Tumor status (T1, etc.)
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Manual of the American Joint Committee on Cancer.
The patients were treated and followed in Tel Aviv
Sourasky Medical Center and in Meir Medical Center.
The study was approved by the Helsinki Committees of
both Centers as a retrospective study based on informa-
tion obtained from files of unidentified patients
(included in the category of studies which do not
require informed consent from study patients).
Immunohistochemistry
In this study, we have used archived paraffin blocks of
patients, all obtained at the time of diagnosis. Serial sec-
tions (5 μmt h i c k )w e r ep r e p a r e df r o mt h eb l o c k sa n d
processed for immunohistochemistry (IHC) by the
Pathology Departments of Tel Aviv Sourasky Medical
Center and Meir Medical Center.
The biopsy sections were deparaffinized, dehydrated in
xylene and graded alcohols, rinsed in PBS and stained
by primary antibodies. All antibodies used in IHC were
commercial monoclonal antibodies, and their ability to
recognize their respective antigens was confirmed in
ELISA assays (data not shown). Staining by primary
monoclonal antibodies for human CCL5 (PeproTech,
Rocky Hill, NJ; Cat# 500-M75) and to human CCL2
(R&D Systems, Minneapolis, MN; Cat# MAB679) was
performed by two protocols that showed similar sensi-
tivity and specificity: (1) Sections were incubated with
hyaluronidase at 37°C for 1 hr, then treated with 3%
H2O2 for 10 min at room temperature (RT). After
Table 1 The characteristics of the DCIS, IDC-no-relapse and IDC-with-relapse patients included in the study
Patient characteristics DCIS IDC -
No Relapse
IDC -
With Relapse
n = 30 (%) n = 23 (%) n = 35 (%)
Menopause
status
Pre-menopause 3 (10.0%) 0 (0.0%) 7 (20.0%)
Menopause 7 (23.3%) 0 (0.0%) 0 (0.0%)
Post-menopause 8 (26.7%) 0 (0.0%) 25 (71.4%)
Unknown 12 (40.0%) 23 (100.0%) 3 (8.6%)
Node status N0 30 (100.0%) 14 (60.9%) 17 (48.6%)
N1 0 (0.0%) 4 (17.4%) 14 (40.0%)
N2 0 (0.0%) 1 (4.4%) 0 (0.0%)
Unknown 0 (0.0%) 4 (17.4%) 4 (11.4%)
Tumor T0 26 (86.7%) 0 (0.0%) 1 (2.9%)
T1 0 (0.0%) 2 (8.7%) 14 (40.0%)
T≥2 0 (0.0%) 19 (82.6%) 17 (48.6%)
Unknown 4 (13.3%) 2 (8.7%) 3 (8.5%)
Grade 1 5 (16.7%) 6 (26.1%) 5 (14.3%)
2 12 (40.0%) 9 (39.1%) 10 (28.6%)
3 6 (20.0%) 5 (21.7%) 7 (20.0%)
Unknown 7 (23.3%) 3 (13.1%) 13 (37.1%)
Radiotherapy Yes 19 (63.4%) 17 (73.9%) 28 (80.0%)
No 10 (33.3%) 5 (21.7%) 5 (14.3%)
Unknown 1 (3.3%) 1 (4.4%) 2 (5.7%)
Chemotherapy Yes 0 (0.0%) 17 (73.9%) 15 (42.9%)
No 18 (60.0%) 5 (21.7%) 17 (48.6%)
Unknown 12 (40.0%) 1 (4.3%) 3 (8.5%)
Her2-neu Yes 3 (10.0%) 1 (4.3%) 6 (17.1%)
No 1 (3.3%) 15 (65.3%) 26 (74.3%)
Unknown 26 (86.7%) 7 (30.4%) 3 (8.6%)
ER Yes 23 (76.7%) 20 (87.0%) 23 (65.7%)
No 2 (6.7%) 2 (8.7%) 10 (28.6%)
Unknown 5 (16.6%) 1 (4.3%) 2 (5.7%)
PR Yes 17 (56.7%) 19 (82.6%) 19 (54.3%)
No 7 (23.3%) 3 (3.0%) 13 (37.1%)
Unknown 6 (20.0%) 1 (4.4%) 3 (8.6%)
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incubating the sections with normal goat serum at 37°C
for 30 min. Then, the sections were stained over night
with the primary antibodies at 4°C, except for sections
of DCIS patients in which the staining was performed
for 4 hr (the time was reduced in this case due to some
background staining that was observed only in the DCIS
biopsies stained by the different antibodies). (2) Sections
were immersed in a staining dish containing citrate buf-
fer at 95-100°C for 22 min, then cooled for 20 min.
After washing with PBS, the sections were blocked with
blocking solution (0.05% sodium azide and 0.05% Tween
20 in PBS). Next, the sections were incubated with the
different primary antibodies for 1 hr at RT, blocked by
3% H2O2 for 10 min at RT, and washed thoroughly in
PBS.
Staining for TNFa and IL-1b was performed accord-
ing to the second procedure detailed above, using
monoclonal antibodies to human TNFa (PeproTech;
Cat# 500-M26) and to human IL-1b (Exalpha, Water-
town, MA; Cat# L140M).
For all four factors (CCL2, CCL5, TNFa and IL-1b),
the staining by secondary antibodies was performed as
follows: sections were washed thoroughly in PBS,
stained with biotinylated anti broad spectrum secondary
antibody, or alternatively, by anti mouse secondary anti-
body (both having similar sensitivity and specificity) for
10 min at RT. After additional washing in PBS, the sec-
tions were stained by HRP-streptavidin for 10 min at
RT. Then, the sections underwent additional washings
in PBS and were incubated with Diaminobenzidine for
10 min at RT, washed and counterstained by incubation
with hematoxylin for 5 sec at RT. After washing in
H2O, the sections were dehydrated in graded alcohols
and mounted to cover slides.
In all cases, negative controls included substitution of
the primary antibodies by PBS, or by non-relevant iso-
type controls. The specificity of the antibodies against
TNFa and IL-1b was verified using mouse IgG1 as an
isotype control for the antibodies (that shared the same
isotype). Also, since the antibodies against CCL5 share
the same isotype with the antibodies against CCL2, but
there were biopsies that stained with one but not with
the other, they served as internal controls for each
other’s specificity (In the 88 breast cancer patients: 9%
of the biopsies stained for CCL2 but not for CCL5, and
25% of the biopsies stained for CCL5 but not for CCL2;
In all other cases, the expression of CCL2 was coordi-
nated with that of CCL5).
All slides were submitted to light microscopy, and
the staining pattern in the cells was evaluated in a
blind manner by a pathologist having expertise in
breast cancer, and by a pathology-experienced
researcher. The tumors were evaluated for %
chemokine/cytokine-positive cells in the tumors (0-
100%) and intensity of expression of the chemokines/
cytokines (1 = low intensity, 2 = medium intensity, 3 =
high intensity). TNFa and IL-1b were also evaluated
for score of expression, determined as “% cytokine-
positive cells in the tumors × the intensity of cytokine
expression in each of the tumors”. In line with the eva-
luations of many other markers in IHC, a threshold for
positive staining was set. Based on our past experience,
non-specific staining (exhibited as rare/sporadic/ran-
dom stainings) could account for up to 5% of the
epithelial cells in the biopsy, therefore the cut-off for
positivity was set on 5%.
The data on expression of Her2-neu, estrogen recep-
tor a (ER) and progesterone receptor (PR) that are
included in Table 1 were provided by Tel Aviv Sourasky
Medical Center and by Meir Medical Center, where the
patients were treated and followed.
Statistical analyses of immunohistochemistry
In this study, a comparison was made between the inci-
dences of expression the different factors in normal
breast epithelial duct cells of the Benign group and the
tumor cells in DCIS, IDC-no-relapse and IDC-with-
relapse groups (Fig. two). This analysis was performed
by Chi-square or two-tailed Fisher’s exact test as applic-
able. Hochberg’s GT2 method for multiple comparisons
was applied for pair-wise comparisons between groups
of patients.
The differences between the incidences of expression
of the different factors in normal breast epithelial cells
that were adjacent to tumor cells in the cancer biopsies,
as compared to the tumor cells in the DCIS, IDC-no-
relapse and IDC-with-relapse groups (Table 2), were
determined by McNemar test (except for TNFa expres-
sion in “IDC-no-relapse” group, that because of limita-
tions of the McNemar test was analyzed by Wilcoxon).
Chi-square or Fisher’s exact test were used in order to
determine the significance of associations between fac-
tors that belonged to “Group 1” (TNFa &I L - 1 b)a n d
f a c t o r st h a tb e l o n g e dt o“Group 2” (CCL2 & CCL5)
(Fig. three).
Group means were compared using a one-way Analy-
sis of Variance (Fig. seven and Table 3). Whenever a
significant effect of group was observed, pair-wise com-
parisons between groups were performed using the
Ryan-Einot-Gabriel-Welsch Multiple Range Test.
Levene’s Test for Homogeneity of Variances was applied
to compare dispersion between groups.
Logistic regression model was applied to assess the
potential use of Her2-neu, ER and PR with cytokines as
risk factors for disease relapse.
All statistical analyses were performed using the SAS
for Windows version 9.1.3.
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The T47D and MCF-7 human breast carcinoma cell
lines were grown in DMEM medium as described pre-
viously [20]. The growth medium was replaced by
serum-deficient medium, and the cells were grown to
confluency in the absence or in the presence of TNFa
or IL-1b for 72 hr.
E-cadherin expression was determined in live cells by
mouse antibodies against human E-cadherin (Santa
Cruz Biotechnology, Santa Cruz, CA), followed by
FITC-conjugated antibodies against mouse IgG (Jackson
ImmunoResearch Laboratories, West Grove, Pennsylva-
nia). Baseline staining was obtained by adding the
appropriate buffer to the cells instead of primary anti-
body, and by staining with non-relevant isotype-treated
antibodies. Determination of vimentin expression was
performed in methanol-treated cells by mouse antibo-
dies against human vimentin (Santa Cruz Biotechnol-
ogy), followed by FITC-conjugated antibodies against
mouse IgG (Jackson ImmunoResearch Laboratories).
Baseline staining was obtained by non-relevant isotype-
matched antibodies. Stainings were determined with a
Becton Dickinson FACSort (Mountain View, CA) using
the CellQuest software.
The expression of b-catenin was determined by speci-
fic antibodies, along with nuclei staining by DAPI. The
cells were fixed by 8% paraformaldehyde for 15 min.
Following treatment by 0.2% triton for 10 min, blocking
was performed with PBS containing 2% BSA for 30 min.
Primary mouse antibodies to human b-catenin were
then used (Santa Cruz Biotechnologies), followed by
FITC-conjugated mouse antibodies against mouse IgG.
Baseline staining was obtained by adding the appropriate
buffer to the cells instead of primary antibody. Similarly
fixed and permeabilized cells were incubated with phal-
loidin-Alexa 488 (Molecular Probes, PoortGebouw, The
Netherlands) for detection of actin organization. Stained
cells were detected by LSM 510 Meta confocal micro-
scope (Carl Zeiss AG, Oberkochen, Germany).
In adhesion assays, TNFa-stimulated cells were trypsi-
n i z e d ,a n dt h e np l a t e di n9 6w e l ln o n - t i s s u ec u l t u r e
plates for 2 hr at 37°C. Non-adherent cells were
removed by washing in PBS. Detection of adherent cells
was performed by an alkaline phosphatase assay, by the
addition of alkaline phosphatase substrate buffer, con-
taining 3 mg/ml p-nitrophenyl phosphate disodium
(Sigma-Aldrich, St. Louis, MO). Following the addition
of 1M NaOH, optical density was measured at 405 nm.
Statistical analysis was performed by Student’s t test.
Migration and invasion assays were performed in
transwell migration chambers with 8-μmp o r es i z e
(Costar, Cambridge, MA). In both assays, MCF-7 cells
were stimulated by TNFa for 48 hr, then added to the
upper wells of the chamber with or without TNFa (in
serum-free DMEM). In invasion assays, the upper wells
were pre-coated with matrigel (20 μg/ml in serum-free
cold DMEM; BD Biosciences, Bedford, MA) for 1 hr at
37°C, then blocking was performed for additional 1 hr
with 0.1% heat inactivated BSA (diluted in PBS). In both
assays, the lower wells of the chamber included 500 μl
Table 2 The incidence of expression of CCL2, CCL5, TNFa and IL-1b in tumor cells and in adjacent normal breast
epithelial cells in DCIS and IDC patients
Expression of chemokines/cytokines
in
Number of patients (%)
With CCL2 expression With CCL5 expression With TNFa expression With IL-1b expression
DCIS
Breast malignant cells 11/27 (40.7%) 16/27 (59.2%) 13/27 (48.1%) 15/27 (55.5%)
Adjacent normal breast epithelial duct cells 5/27 (18.5%) 7/27 (25.9%) 3/27 (11.1%) 6/27 (22.2%)
p value 0.03 0.01 0.002 0.003
IDC-no-relapse
Breast malignant cells 10/19 (52.6%) 15/19 (78.9%) 14/19 (73.7%) 13/19 (68.4%)
Adjacent normal breast epithelial duct cells 1/19 (5.3%) 1/19 (5.3%) 0/19 (0.0%) 1/19 (5.3%)
p value 0.003 0.0002 0.0001 0.0005
IDC-with-relapse
Breast malignant cells 15/29 (51.7%) 17/29 (58.6%) 24/29 (82.7%) 25/29 (86.2%)
Adjacent normal breast epithelial duct cells 3/29 (10.3%) 2/29 (6.9%) 6/29 (20.7%) 8/29 (27.6%)
p value 0.001 0.0001 <0.0001 <0.0001
The expression CCL2, CCL5, TNFa and IL-1b was determined by IHC in serial biopsy sections of primary tumors of the breast taken at the time of diagnosis, from
patients diagnosed with DCIS, IDC-no-relapse, or IDC-with-relapse. In this analysis, the incidences of expression of the four factors were determined in the
malignant cells and in adjacent normal breast epithelial cells, in the same biopsy. Therefore, this analysis included only patients in whom normal ducts and
breast tumor cells were detected in the same biopsy: DCIS - n = 27; IDC-no-relapse - n = 19; “IDC-with-relapse - n = 29. The incidence of CCL2, CCL5, TNFa and
IL-1b expression in the normal epithelium was not significantly different between DCIS and IDC-no-relapse, and also did not differ significantly between DCIS and
IDC-with-relapse patients. The expression of the proteins was determined by antibodies whose binding specificity in IHC was verified.
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hr of incubation, the cells on the upper surface of the
filter were completely removed by wiping with a cotton
swab. The filters were fixed (by methanol in migration
assays and by 4% paraformaldehyde in invasion assays)
and were stained with Diff-Quik (Dade Behring, Newark,
DE). The cells were counted in high power fields (HPF)
by light microscopy. Statistical analysis was performed
by Student’s t test.
Results
Patterns of expression of inflammatory chemokines and
cytokines, determined by immunohistochemistry
Biopsy sections were obtained from the total of 126
individuals (as indicated in “Materials and methods”)a t
t h et i m eo fd i a g n o s i s ,a n dw e r es t a i n e db ys p e c i f i ca n t i -
bodies that recognized human CCL2, CCL5, TNFa or
IL-1b. Figure 1 displays representative examples of the
staining patterns of the four proteins in biopsy sections
of healthy individuals (the “Benign” group), and of
DCIS, IDC-no-relapse and IDC-with-relapse patients.
While the expression of CCL2, CCL5, TNFa or IL-1b
was only minimally detected in infiltrating leukocytes of
all groups of patients, the four factors were clearly
observed in breast tumor cells, with mainly a cytoplas-
mic staining pattern. Based on the above, we have per-
formed detailed analysis of the expression patterns of
the four factors in breast epithelial cells, normal and
malignant, in biopsy sections of healthy individuals and
of breast cancer patients, as indicated below.
Protein expression in normal and malignant epithelial
breast cells
Figure 2 provides information on the incidences of
expression of CCL2, CCL5, TNFa and IL-1b in normal
breast epithelial cells of Benign patients, and in the
tumor cells in patients diagnosed with DCIS, IDC-no-
relapse and IDC-with-relapse. All four factors were
minimally detected in normal breast epithelial duct cells
in the healthy individuals of the Benign group (expres-
sion incidences ranging between 5.3% and 10.5%). A sig-
nificant elevation was denoted in the expression of
CCL2, CCL5, TNFa and IL-1b in the tumor cells in all
groups of cancer patients (DCIS, IDC-no-relapse and
IDC-with-relapse), when compared to their expression
in the normal breast cells in biopsies of the Benign
patients, with significance value of p < 0.001 in all cases.
In parallel, we determined the expression of CCL2,
CCL5, TNFa and IL-1b in normal breast epithelial duct
cells that were in proximity to the tumor cells in biop-
sies of patients with DCIS, IDC-no-relapse and IDC-
with-relapse (Table 2). In these three groups of cancer
patients, we found low incidence of expression of the
inflammatory chemokines and inflammatory cytokines
in the normal cells adjacent to the tumor cells, while
they were expressed at significantly higher incidence in
the tumor cells (incidences and p values are presented
in Table 2). The incidence of CCL2, CCL5, TNFa and
IL-1b expression in the normal epithelium was not sig-
nificantly different between DCIS and IDC-no-relapse,
and also did not differ significantly between DCIS and
IDC-with-relapse patients.
Taken together, these findings indicate that the
expression of the inflammatory chemokines and inflam-
matory cytokines was acquired by breast epithelial cells
upon their malignant transformation.
Protein expression along stages of disease progression
Next, we compared the three groups of breast cancer
patients (DCIS, IDC-no-relapse, IDC-with-relapse) with
respect to the incidence of expression of CCL2, CCL5,
TNFa and IL-1b in the tumor cells. The results of Fig-
ure 2 clearly show that the expression of the inflamma-
tory chemokines CCL2 and CCL5 remained high and
constant in the tumor cells of DCIS, IDC-no-relapse
Table 3 TNFa and IL-1b prevalence in tumors of breast
cancer patients
Cytokine Group
No.
Group
name
% Positive cells in
tumors
(X ± SD)
Score
(X ± SD)
TNFa I DCIS 67.3 ± 24.7 134.8 ± 82.4
II IDC-no-
relapse
65.9 ± 23.7 141.9 ± 81.1
III IDC-with-
relapse
85.0 ± 6.8 191.0 ± 70.3
p value 0.0008 0.0331
IL-1b I DCIS 69.3 ± 21.6 117.6 ± 80.1
II IDC-no-
relapse
55.7 ± 29.3 121.2 ± 96.5
III IDC-with-
relapse
84.8 ± 11.5 206.2 ± 76.2
p value <0.0001 0.0004
The table provides information on the prevalence of TNFa and IL-1b
expression in tumors of breast cancer patients, with analyses that were
performed only on patients whose tumors expressed the cytokines: DCIS
group = Group I: TNFa n = 15, IL-1b n = 18; IDC-no-relapse group = Group II:
TNFa n = 17, IL-1b n = 15; IDC-with-relapse group = Group III: TNFa n = 29,
IL-1b n = 31. Each of the TNFa- and IL-1b-positive tumors were analyzed for
% positive cells in the tumors, intensity of expression of the cytokines, and
score (as described in “Materials and methods”). The table provides the X ±
SD of % cells positive for TNFa and IL-1b, and the X ± SD of the expression
scores of TNFa and IL-1b in the three groups of patients.
For each cytokine, group means were compared by one-way analysis of
variance. Whenever a significant effect of group was observed, pair-wise
comparisons between groups were performed. The results of the statistical
analyses have shown that: (1) For % TNFa-positive cells, p = 0.0008: Group III
was statistically different from Groups I and II. (2) For TNFa score, p = 0.0331:
Paired comparisons did not identify specific significant differences between
the groups of patients. (3) For % IL-1b positive cells, p < 0.0001: All three
groups were statistically different from each other. (4) For IL-1b score, p =
0.0004: Group III was statistically different from Groups I and II.
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b. Ductal Carcinoma In Situ
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a4. IL-1β
b4. IL-1β
c4. IL-1β
d4. IL-1β d3. TNFα
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x200 x200
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Figure 1 Expression patterns of CCL2, CCL5, TNFa and IL-1b in healthy individuals and breast cancer patients. Representative examples
of the expression of CCL2, CCL5, TNFa and IL-1b in the different groups of patients included in the study, in biopsies obtained at the time of
diagnosis. (a1-a4) Patients diagnosed with benign breast disorders. The pictures demonstrate the lack of staining of the four factors in the
normal breast epithelial cells, as denoted in the majority of patients included in this group. (b1-b4) DCIS patients. The pictures demonstrate
positive staining of the four factors in the malignant lesions, as denoted in the majority of patients included in this group. (c1-c4) IDC-no-relapse
patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this
group. (d1-d4) IDC-with-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the
majority of patients included in this group. (a1, b1, c1, d1) CCL2 staining; (a2, b2, c2, d2) CCL5 staining; (a3, b3, c3, d3) TNFa staining; (a4, b4, c4,
d4) IL-1b staining. The expression of the proteins was determined by IHC using specific antibodies, whose specificity in IHC was verified. The
values of photo magnification are indicated in the left bottom corner of each of the pictures.
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Page 7 of 20and IDC-with-relapse patients. No significant differences
were denoted between DCIS, IDC-no-relapse and IDC-
with-relapse patients, with respect to the incidence of
CCL2 and CCL5 expression in the tumor cells.
A high incidence of expression in the tumor cells was
also denoted for TNFa and IL-1b in the three groups of
cancer patients: DCIS, IDC-no-relapse and IDC-with-
relapse. The results of Figure 2 indicate that the inci-
dence of TNFa expression was 50% in DCIS patients and
was significantly increased to 85.7% in IDC-with-relapse
patients (p = 0.005); Similarly, the incidence of IL-1b was
significantly raised from 60% in DCIS to 88.6% in IDC-
with-relapse patients (p = 0.017). No other significant dif-
ferences were found between the different groups of
breast cancer patients with respect to TNFa and IL-1b
expression in the tumor cells (namely: IDC-no-relapse vs.
DCIS; IDC-no-relapse vs. IDC-with-relapse).
Together, these findings indicate that there was high
incidence of CCL2, CCL5, TNFa and IL-1b expression
in the tumor cells in the three groups of cancer patients,
and that the expression of TNFa and IL-1b was further
elevated in the IDC-with-relapse group. The rare expres-
sion of all four factors in normal breast epithelial cells,
and the high incidence of their expression in tumor
cells in biopsies of all groups of cancer patients, indicate
that the expression of the inflammatory chemokines
CCL2 & CCL5 is coordinated with that of the inflamma-
tory cytokines TNFa &I L - 1 b along stages of tumor
development and progression in breast cancer.
Dependence between the inflammatory chemokines and
the inflammatory cytokines along disease progression
Based on the above results, we asked whether there are
associations between the inflammatory chemokines
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Figure 2 Incidence of expression of CCL2, CCL5, TNFa and IL-1b in healthy individuals and breast cancer patients. The expression of
CCL2, CCL5, TNFa and IL-1b was determined by IHC in four groups of patients, in biopsies obtained at the time of diagnosis: Benign (n = 38),
DCIS (n = 30), IDC-no-relapse (n = 23) and IDC-with-relapse (n = 35). The incidences of expression of the four factors are diagrammed according
to the type of factor analyzed. The number of patients positive for protein expression is indicated above the relevant bar, and the incidence is
presented in percentages. ***p < 0.001 for the differences between the incidences of expression of each factor in the tumor cells of DCIS/IDC-
no-relapse/IDC-with-relapse, and the incidence of its expression in the normal cells of the Benign group. No significant differences were denoted
with respect to CCL2 and CCL5 expression in the tumor cells between the DCIS, IDC-no-relapse and IDC-with-relapse groups. For TNFa and IL-
1b expression in the tumor cells, significant elevations were denoted only for the incidence of expression between the DCIS and the IDC-with-
relapse groups (TNFa: p = 0.005; IL-1b: p = 0.017).
Soria et al. BMC Cancer 2011, 11:130
http://www.biomedcentral.com/1471-2407/11/130
Page 8 of 20CCL2 & CCL5 and the inflammatory cytokines TNFa &
IL-1b in patients representing different stages along the
progression process of breast cancer. To this end, we
divided the four factors to two groups, based on their
published functional interactions in breast tumor cells:
Group 1 - The inflammatory cytokines TNFa &I L - 1 b,
which promote the release of CCL2 & CCL5 by breast
tumor cells; Group 2 - The inflammatory chemokines
CCL2 & CCL5, whose release by malignant breast cells
is increased by TNFa and IL-1b (Please refer to Addi-
tional Files 1 and 2, as well as to references [65-70].
These analyses were performed in the tumor cells in the
three groups of cancer patients: DCIS, IDC-no-relapse
and IDC-with-relapse.
When we analyzed the DCIS group, we found that
factors belonging to Group 1 (TNFa &I L - 1 b) “tended”
to be expressed in the same biopsies in which the fac-
tors of group 2 were expressed (CCL2 & CCL5) (Figure
3a). For example, the study of CCL2 showed that CCL2
was co-expressed with TNFa and IL-1b in 33.3% of the
DCIS biopsies. In contrast, in only 10% of the DCIS
patients CCL2 was detected without co-expression of
TNFa and IL-1b. This finding indicates that there was a
preferential expression of CCL2, as a representative of
Group 2, with factors that belonged to Group 1, namely
TNFa & IL-1b.
Similar analyses that were performed for the other
three factors in DCIS patients - CCL5, TNFa and IL-1b
- have shown similar trends to those obtained for CCL2,
namely that the inflammatory chemokines “favored” co-
expression with the inflammatory cytokines, and vice
versa. Accordingly, the statistical analyses that were pre-
formed in DCIS patients demonstrated that the factors
of Group 1 were significantly associated with the factors
of Group 2 (p = 0.002), indicating that in this group of
patients there were defined associations between the
inflammatory chemokines and the inflammatory
cytokines.
Thereafter, analyses that were performed for patients
diagnosed with IDC-no-relapse have shown that the
expression of CCL2 & CCL5 was coordinated with that
of TNFa &I L - 1 b (Figure 3b). This was substantiated by
significant associations that were detected between fac-
tors of Group 1 (TNFa & IL-1b) and Group 2 (CCL2 &
CCL5), with p = 0.036.
A somewhat different pattern of expression was
obtained for IDC-with-relapse patients (Figure 3c). As
in the DCIS and IDC-no-relapse groups, the incidence
of CCL2 and CCL5 in the IDC-with-relapse group
remained at the level of 50-65%; however, the inci-
dence of TNFa and IL-1b expression in the IDC-with-
relapse group was increased to 85-90% (Figure 2).
Therefore, in many of the patients of this group, the
expression of TNFa &I L - 1 b was coordinated with
that of CCL2 & CCL5, but in others the expression of
TNFa &I L - 1 b was not accompanied by expression of
CCL2 & CCL5. This has led to insignificant associa-
tions (p = 0.627) between Group 1 (the inflammatory
cytokines TNFa &I L - 1 b) and Group 2 (the inflamma-
tory chemokines CCL2 & CCL5) in the IDC-with-
relapse group.
To conclude, in patients that belonged to the DCIS
and IDC-no-relapse groups, the expression of the
inflammatory chemokines was coordinated and signifi-
cantly associated with that of the inflammatory cyto-
kines. In contrast, in the IDC-with-relapse group there
was sub-population of patients in which the expression
of CCL2 & CCL5 did not accompany the expression of
TNFa &I L - 1 b. In this group of IDC-with-relapse
patients, the expression of TNFa &I L - 1 b was further
elevated and was highly prevalent, supporting an impor-
tant role for TNFa and IL-1b in disease progression and
recurrence. Furthermore, these results suggest that in
this specific sub-group of IDC-with-relapse patients, the
two cytokines are coordinated with other tumor-sup-
porting factors that replace CCL2 & CCL5 in promoting
disease relapse.
The persistence of inflammatory cytokines in breast
tumors may promote disease progression and recurrence,
e.g. via epithelial-to-mesenchymal transition
The findings on the elevated expression of TNFa and
IL-1b in the IDC-with-relapse group suggest that these
two cytokines support disease progression. In addition
to the tumor-promoting activities of TNFa and IL-1b
that have already been described, it is possible that these
two cytokines also have functional interactions with
CCL2 and CCL5, by that promoting disease course. In
line with this possibility, our findings have shown that
TNFa and IL-1b up-regulated the release of CCL2 and
CCL5 by breast tumor cells (Additional Files 1 and 2;
also suggested by findings of references [65-70]). Such a
cross-talk may lead to up-regulated expression of CCL2
and CCL5 in tumors expressing TNFa and/or IL-1b,
thus possibly leading to increased tumor-supporting
activities of the two chemokines in breast tumors (see
Discussion, below).
In addition to their ability to promote the release of
CCL2 and CCL5 by the tumor cells, it is possible that
TNFa and IL-1b act directly to elevate processes that
are required for local recurrence or metastasis forma-
tion, which identify the IDC-with-relapse group of
patients. Recent studies indicate that acquisition of self-
renewal properties that are required for formation of
recurrent local tumors, as well as metastasis formation,
are promoted by Epithelial-to-Mesenchymal Transition
(EMT) processes [71-77]. Based on the above, we deter-
mined the possibility that TNFa and IL-1b promote
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for associations between Group 1 and Group 2. (b) In IDC-no-relapse patients, p = 0.036 for associations between Group 1 and Group 2. (c) In
IDC-with-relapse patients, p = 0.627 for associations between Group 1 and Group 2. Explanation: In each group of breast cancer patients (DCIS,
IDC-no-relapse, IDC-with-relapse), the graphs show the following: (1) CCL2: The graph shows the incidence of CCL2 expression when it was co-
expressed with TNFa and IL-1b in the same biopsy [presented in the graph as “CCL2 (+ TNFa) (+ IL-1b)"], as compared to the incidence of CCL2
expression when it was NOT co-expressed with TNFa and IL-1b in the same biopsy [presented in the graph as “CCL2 (- TNFa) (- IL-1b)"]; (2)
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Page 10 of 20EMT processes in the tumor cells, thus pushing forward
disease recurrence and progression.
To investigate this possibility, we tested the ability of
TNFa and IL-1b to induce in the tumor cells properties
that are typical of EMT [71-77]. In these experiments,
we used the T47D and MCF-7 cells, which represent a
non-advanced stage of breast malignancy [78-82], and
thus can serve as an appropriate platform for induction
of EMT processes that are associated with more pro-
gressed disease.
First, we stimulated the cells by TNFa and IL-1b
(please see “Note” in legend to Figure 4 on cytokine
concentrations used in these analyses), and determined
the ability of the cytokines to induce reduction in the
membranous expression of E-cadherin, an adhesion
molecule which is important in establishing cell-to-cell
contacts. The results of Figures 4a and 4b demonstrate
that TNFa potently induced a very typical property of
E M T ,n a m e l yr e d u c t i o ni nE - c a d h e r i ne x p r e s s i o na tt h e
cell membrane of the tumor cells. This activity of TNFa
was induced in both the T47D and the MCF-7 cells in a
dose-dependent manner. In parallel, stimulation by IL-
1b has also led to reduced expression of E-cadherin at
the plasma membrane, but only in the T47D cells (Fig-
ure 4c).
Based on these results and on additional preliminary
findings (data not shown), we suspected that TNFa was
a more potent inducer of EMT than IL-1b,a n dt h a ti t s
effects were more prominent on MCF-7 cells than on
T47D cells. Therefore in depth analyses were continued
with TNFa, analyzed on MCF-7 cells only. Further ana-
lyses indicated that TNFa has led to substantial
decrease in the expression of b-catenin at the cell mem-
brane of the tumor cells (Figure 4d), an event which is
typical of EMT. Also, the stimulation by the cytokine
has promoted the expression of vimentin, a mesenchy-
mal feature whose expression is elevated in cells under-
going EMT (Figure 5a). In parallel, the tumor cells have
acquired cellular protrusions, accompanied by extensive
re-organization of the actin cytoskeleton (Figures 5b and
5c, respectively).
In addition to the above, TNFa has induced in the
tumor cells elevated adhesion to substrate, a step neces-
sary for establishment of productive metastases at
remote organs (Figure 6a). Importantly, following TNFa
stimulation, the cells have acquired the most critical and
metastasis-relevant property of EMT, namely increased
migratory and invasive properties (Figures 6b and 6c),
by that substantiating the ability of the cytokine to
induce EMT in breast tumor cells.
Taken together, the above results indicate that TNFa,
and possibly also IL-1b - although to a lower extent -
induced EMT properties in the tumor cells. Of note,
similar activities of the two cytokines were obtained in
an unrelated ongoing study in our laboratory, performed
on a different set of breast cells (data not shown; manu-
script in preparation), further substantiating the EMT-
promoting activities of TNFa and IL-1b. Also, prelimin-
a r ya n a l y s e st h a tw eh a v ep e r f o r m e di n d i c a t e dt h a t
CCL2 and CCL5 were not capable of inducing EMT-
related processes in the breast tumor cells (data not
shown).
Since the potent EMT-promoting activities of TNFa
may push forward processes of increased metastasis for-
mation and disease recurrence, we further addressed the
characteristics of TNFa activity. In view of reports
showing that the EMT phenotype may be transient and
needs continuous exposure to EMT-inducing factors
[72], we asked if induction of EMT by TNFa required
constant stimulation by the cytokine. To determine this
issue, we have taken cells in which EMT was induced
by TNFa (as indicated by reduced expression of E-cad-
herin at the cell membrane), and extended their growth
for additional 72 hr with or without TNFa.T h er e s u l t s
of Figure 7 clearly indicate that the EMT phenotype was
reversible if the cells were deprived of TNFa, while in
cells that were grown continuously with the cytokine
the EMT phenotype was preserved.
The above findings suggest that breast tumor cells
benefit from high and constant presence of TNFa,
because the persistence of the cytokine may induce
EMT processes that lead to progressed and recurred dis-
ease. In such a case, we would expect that TNFa would
be more persistent in tumors of IDC patients who
relapsed with metastases or local tumors, compared to
IDC-no-relapse or to DCIS patients.
To find out if this was indeed the case, we determined
in each of the three groups of breast cancer patients
(DCIS, IDC-no-relapse, IDC-with-relapse) the para-
meters of % TNFa-positive cells in the tumors, and the
score of TNFa expression. The results presented in Fig-
ure 8a and in Table 3 demonstrate that there was a sig-
nificant elevation in % TNFa-positive cells/patient in
the IDC-with-relapse group when it was compared to
DCIS and to the IDC-no-relapse groups, where p =
0.0008 for % TNFa-positive cells, and p = 0.0331 for
TNFa score (as indicated in the legend to Table 3).
Of note, similar analyses that were performed for IL-
1b have also shown highly significant persistence of this
cytokine in tumors of IDC-with-relapse patients, with p
<0 . 0 0 0 1f o r%I L - 1 b-positive cells, and p = 0.0004 for
IL-1b score (Figure 8b and Table 3). These results sug-
gest that persistence of IL-1b i nt h et u m o r si sa l s o
important for driving forward processes of progression
and recurrence. Based on our data, these activities of IL-
1b are not necessarily related to EMT, because this
cytokine was not as effective in this function as TNFa.
Rather, IL-1b may acquire activities that are related for
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Figure 4 Following stimulation by the inflammatory cytokines (mainly TNFa), the tumor cells show typical characteristics of EMT. The
T47D and MCF-7 human breast carcinoma cells were stimulated by TNFa and IL-1b for 72 hr. Note: The cytokine concentrations were chosen
based on analyses in which their effects on the tumor cells were tested in a dose-dependent manner (data not shown). (a) Stimulation of T47D
cells with 300 U/ml TNFa (a1) or with 1000 U/ml TNFa (a2). The membranous expression of E-cadherin was determined in live cells by flow
cytometry. The figure presents the results of a representative experiment of n = 3, all showing similar results. (b) Stimulation of MCF-7 cells with
300 U/ml TNFa (b1) or 1000 U/ml TNFa (b2). The membranous expression of E-cadherin was determined in live cells by flow cytometry. The
figure presents the results of a representative experiment of n > 3, all showing similar results. (c) T47D human breast carcinoma cells were
stimulated by IL-1b (500 pg/ml). The membranous expression of E-cadherin was determined in live cells by flow cytometry. The figure presents
the results of a representative experiment of n = 3, all showing similar results. (d) MCF-7 cells were stimulated by 1000 U/ml TNFa, and b-
catenin expression (green) was determined by confocal analyses, in fixed cells. Nuclei are shown by blue DAPI staining. The figure presents the
results of a representative experiment of n = 3, all showing similar results.
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Figure 6 Following stimulation by TNFa, breast tumor cells acquire increased adhesive, migratory and invasive properties.M C F - 7
breast carcinoma cells were stimulated by TNFa (1000 U/ml). Thereafter, the following analyses were performed: (a) Following 72 hr stimulation
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Page 14 of 20example to elevated angiogenesis, as previously sug-
gested [28,31,83]. In addition, it is possible that IL-1b
acts jointly with other pro-malignancy factors to pro-
mote disease progression and recurrence. Such addi-
tional factors could be related to the response of the
tumor cells to growth factors that are found at the
tumor microenvironment, or to hormonal stimulation.
Supporting this possibility are analyses that we have
performed, using the data obtained on the expression of
Her2-neu, ER and PR in the patients. In this analysis,
we have compared between the IDC-no-relapse and the
IDC-with-relapse groups. Statistical analysis that was
performed for IL-1b, taking into account the status of
Her2-neu, ER and PR, all combined (currently each of
these three factors is used in the clinic as predictors of
disease progression and recurrence in breast cancer),
indicated that IL-1b was a significant risk factor for
disease relapse: p = 0.0402, with 95% confidence limits
of 1.098 and 59.93 and odds ratio 1 value of 8.112 (also,
of the different clinical markers, PR was statistically dif-
ferent between the IDC-no-relapse and IDC-with-
relapse groups, with p = 0.0391). Similar analyses per-
formed for TNFa, CCL2 and CCL5 did not reveal sig-
nificant positive correlation with disease progression.
The findings on IL-1b strongly support the possibility
that when the tumor-derived and/or microenvironment-
derived characteristics have higher cancer-promoting
properties, IL-1b can further promote progression-
related processes in breast cancer.
Discussion
In this study, we have identified the relationships
between inflammatory chemokines and cytokines in
breast cancer along different stages of disease, and have
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Page 15 of 20analyzed the potential roles of TNFa and IL-1b in pro-
moting breast cancer progression. The results of this
study shed light on the inflammatory setup in breast
cancer, and provide three novel findings:
(1) The expression of the inflammatory chemokines CCL2
& CCL5 and of the inflammatory cytokines TNFa & IL-1b
is coordinated in breast cancer
To date, the relationships between inflammatory chemo-
kines and inflammatory cytokines in breast cancer were
not elucidated, and the associations between them dur-
ing the process of breast cancer development and pro-
gression were not analyzed. At this setting, the findings
of our study are important because they indicate that
the expression of the inflammatory chemokines CCL2 &
CCL5 and of the inflammatory cytokines TNFa & IL-1b
is coordinated in crucial stages along the process of dis-
ease progression. Moreover, the expression of all four
inflammatory factors is minimal in normal breast
epithelial cells, and is simultaneously acquired by the
cells once malignant transformation has taken place,
namely from the DCIS stage and on. These results sug-
gest that events dictated by genetic/epigenetic altera-
tions in the tumor cells, or by the microenvironment,
lead to a synchronized up-regulation in the expression
of several inflammatory mediators together, by trans-
formed breast epithelial cells.
The coordinated expression of CCL2 & CCL5 and of
TNFa & IL-1b along stages of breast cancer development
and progression is important because the activities of the
four factors are not fully overlapping (Refs [3,5-24] for
CCL2 & CCL5, [25-59] for TNFa and IL-1b). Therefore,
it is possible that each of these factors contributes its
own share to disease course, alongside with the others.
Together, the coordinated presence of CCL2 & CCL5
and of TNFa &I L - 1 b may support malignancy, possibly
also due to spatio-temporal cross-interactions between
them. Indeed, our findings (Additional Files 1 and 2) and
published studies [65-70] indicate that TNFa and IL-1b
up-regulate the release of CCL2 and CCL5 by breast
tumor cells. Furthermore, recent findings obtained in our
studies suggest that TNFa and IL-1b exert tumor-pro-
moting activities that are connected to the ability of
CCL2 and CCL5 to function as cancer-supporting fac-
tors. Consequently, it is possible that the pro-tumorigenic
activities of the inflammatory cytokines and of the
inflammatory chemokines depend on each other, and/or
are complementary to one another. This possibility
emphasizes the need to determine whether combined
inhibition of all factors together will lead to improved
limitation of tumor growth.
Moreover, since our findings indicate that the coordi-
nated array of cytokines and chemokines takes action in
about 50-70% of the patients (depending on the group), it
is possible that these factors can act along with other
inflammatory and tumor-supporting factors to promote
tumor growth and metastasis, as further discussed below.
(2) The expression of TNFa & IL-1b is further increased in
the IDC-with-relapse group of patients
In the group of IDC-with-relapse patients, the incidence of
CCL2 & CCL5 expression was similarly high to that of
DCIS and IDC-no-relapse group (50-65%), while that of
TNFa &I L - 1 b has reached about 85-90%. Therefore,
while the expression of CCL2 & CCL5 was coordinated
with TNFa &I L - 1 b in many of the patients belonging to
this group, there was a sub-population of patients in
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Figure 8 There is high persistence of TNFa and IL-1b in tumors
of IDC-with-relapse patients. (a) Analyses of % cells that were
positive for TNFa in tumors of breast cancer patients. The figure
shows analyses that were performed only in patients whose tumors
were positive for TNFa expression: DCIS (n = 15); IDC-no-relapse (n
= 17); IDC-with-relapse (n = 29). Each symbol in the graph
represents a single patient. Statistical values, as well as X ± SD are
provided in Table 3. (b) Analyses of % cells that were positive for IL-
1b in tumors of breast cancer patients. The figure shows analyses
that were performed only in patients whose tumors were positive
for IL-1b expression: DCIS (n = 18); IDC-no-relapse (n = 15); IDC-
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patient. Statistical values, as well as X ± SD are provided in Table 3.
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Page 16 of 20which the expression of TNFa &I L - 1 b was not accompa-
nied by CCL2 & CCL5. While we need to understand the
reasons for this lack of coordination in this specific sub-
group of patients (please see discussion below), this obser-
vation indicates that TNFa &I L - 1 b are required, and play
important roles in disease progression, and suggests that
they cooperate with other factors at the tumor microenvir-
onment that substitute for the lack of CCL2 & CCL5.
Of interest in this respect are the reasons for the lack
of expression of CCL2 & CCL5 in the specific sub-
population of IDC-with-relapse patients who do express
TNFa &I L - 1 b. This lack of coordination between
CCL2 & CCL5 and TNFa &I L - 1 b in this sub-popula-
tion is intriguing mainly because TNFa and IL-1b were
found to stimulate the release of CCL2 and CCL5 by
breast tumor cells. The explanation could be given, at
least partly, by consideration of the extent to which
receptors for TNFa and IL-1b are expressed by the
tumor cells, and of which type. Although the expression
of TNFa &I L - 1 b receptors by breast tumor cells was
already documented [29,31,37,43,44], it is possible that
in this specific sub-group of the IDC-with-recurrence
patients, the tumor cells do not express the required
receptors for TNFa &I L - 1 b, or express non-signaling
receptors. Under such conditions, TNFa &I L - 1 b would
not act on the tumor cells to promote the release of
CCL2 & CCL5, leading to lack of associations between
the two cytokines and CCL2 & CCL5.
Accordingly, in our future investigations we will per-
form detailed analysis of the expression of receptors for
the two cytokines (e.g. TNFRI, TNFRII, IL-1RI) in the
course of disease progression in breast cancer. Such an
analysis may enable us to better identify the basis for
the patterns of expression of the inflammatory cytokines
and chemokines in different stages of disease.
(3) Tumors of IDC-with-relapse patients express persistent
and high levels of TNFa & IL-1b, which may contribute to
disease recurrence and progression, e.g. via EMT
As indicated above, the incidence of TNFa &I L - 1 b was
further increased in IDC patients in whom disease has
relapsed, suggesting that these two cytokines push for-
ward processes of tumor progression and recurrence.
Our findings support this possibility because they indi-
cate that TNFa, and to a lower extent also IL-1b, induce
EMT properties in the tumor cells.
In addition, our findings demonstrate that in order to
undergo EMT, the tumor cells had to be constantly sti-
mulated by TNFa. These results suggest that in situ,
EMT processes would be facilitated by high persistence
of TNFa at the tumor site. Under such conditions, we
would expect high prevalence of TNFa in tumors of
patients belonging to the IDC-with-relapse group,
compared to IDC-no-relapse or to DCIS patients.
Indeed, here we have obtained an important indication
to the roles of TNFa in disease recurrence and progres-
sion, because there was significantly higher prevalence
of TNFa in tumors of the IDC-with-relapse group than
in the other two groups of cancer patients. In addition,
significantly elevated persistence of IL-1b was also
observed in the IDC-with-relapse patients. Although IL-
1b was not a strong stimulant of EMT, it is possible
that this cytokine supports tumor recurrence or metas-
tasis by other means, such as increased angiogenesis, as
indicated by several published studies [28,31,83], or by
having joint activity with other factors. Supporting this
possibility is the finding that in a specific setting of
Her2-neu, ER and PR expression in the tumors, IL-1b
was identified as a risk factor for disease recurrence,
suggesting that it can act jointly with other pro-malig-
nancy factors to promote disease progression in breast
cancer.
The observations that were obtained in this part of the
study support the possibilityt h a th i g hp r e v a l e n c eo f
TNFa and IL-1b expression in the IDC-with-relapse
patients contributes to re-growth of the tumors and to
metastasis formation by inducing processes that push
forward these processes, e.g. via EMT and/or coopera-
tive activity with other pro-malignancy factors that are
expressed by the tumor cells, or by cells of the tumor
microenvironment.
Conclusions
Our study is the first to provide detailed analysis of the
expression of inflammatory chemokines, alongside with
inflammatory cytokines, in different progression stages
of breast cancer. We provide evidence to a coordinated
expression of the inflammatory chemokines CCL2 &
CCL5 and the inflammatory cytokines TNFa & IL-1b in
breast cancer, all having causative roles as tumor-pro-
moting factors in this disease.
Our study also emphasizes the importance of TNFa
and IL-1b in promoting disease metastasis and recur-
rence, gaining support by their high prevalence in
patients in whom disease has relapsed. Such advantages
could be given to the tumor cells by the ability of TNFa
to promote EMT, and by similar (although to a lower
extent) or other tumor-promoting activities of IL-1b (e.
g. joint activities with other pro-malignancy elements).
Mainly, the findings on TNFa contribute to the overall
view of the roles played by this cytokine in breast can-
cer. While TNFa was found to have multiple tumor-
promoting roles in this disease [25-59,84], there are
malignant diseases in which it was described as an anti-
malignancy factor [25,60,61]. Our present results pro-
vide further evidence to the major importance of TNFa
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Page 17 of 20in supporting breast malignancy, and strengthen the
need to consider this cytokine as a therapeutic target in
this disease.
Based on our findings, the possibility exists that differ-
ent inflammatory mediators act in complementary man-
ners at the tumor microenvironment to support
processes of tumor growth and progression, with poten-
tially major roles for TNFa. Such a possibility empha-
sizes the need to perform extensive in vitro and in vivo
studies, in which the combined roles of such factors will
be investigated, to be then followed by determining the
effects of joint inhibitory measures on disease course.
Indeed, in our analyses we are now taking the first steps
in this direction. It is possible that such an approach
may hamper different pro-tumorigenic mechanisms and
signaling pathways simultaneously, leading to more inhi-
bitory effects on breast tumor growth and metastasis.
Additional material
Additional file 1: TNFa and IL-1b up-regulate the release of CCL2 by
human breast tumor cells. T47D (A) and MCF-7 (B) human breast
tumor cells were stimulated for 24-48 hr with human TNFa or IL-1b.
CCL2 levels were determined in the cell supernatants by ELISA, at the
linear range of absorbance. The results are representatives of n ≥ 3. *p <
0.05, **p < 0.01 in comparison to unstimulated cells.
Additional file 2: TNFa and IL-1b up-regulate the release of CCL5 by
human breast tumor cells. T47D (A) and MCF-7 (B) human breast
tumor cells were stimulated for 24-48 hr with human TNFa or IL-1b.
CCL5 levels were determined in the cell supernatants by ELISA, at the
linear range of absorbance. The results are representatives of n ≥ 3. **p
< 0.01, ***p < 0.001 in comparison to unstimulated cells.
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